Sale of sterile syringes for prevention of disease, see §325-21.
[§325-116] Reports. The department, on or before January 1 of each year, shall submit a report to the oversight committee. The report shall include:
(1) Information as to the number of participants served and the number of needles and syringes distributed;
(2) A demographic profile of the participants served, including but not limited to: age, sex, ethnicity, area of residence, occupation, types of drugs used, length of drug use, and frequency of injection;
(3) Impact of the program on needle and syringe sharing and other high risk behavior;
(4) Data on participants regarding HIV testing, counseling, drug treatment, and other social services, including referrals for HIV testing and counseling and for drug abuse treatment;
(5) Impact on the transmission of HIV infection among injection drug users;
(6) Impact on behaviors that caused participants to be at risk for HIV transmission such as frequency of drug use and needle sharing;
(7) An assessment of the cost-effectiveness of the program versus direct and indirect costs of HIV infection; and
(8) Information on the percentage of persons served through treatment programs for injection drug users funded through the department that were attributed to needle exchange referrals.
The report shall address the strengths and weaknesses of the program, the advisability of its continuation, amendments to the law, if appropriate, and other matters that may be helpful to the oversight committee in evaluating the program's efficacy. [L 1992, c 152, pt of §2]Section: Previous 325-103 325-104 325-111 325-112 325-113 325-114 325-115 325-116 325-117 325-121 325-122 325-123 325-124 325-125 325-126 Next
Last modified: October 27, 2016